Benefits of deacetylase inhibitors for leukemia therapy
The consequences of epigenetic drugs in the treatment of AML
Germline predispositions in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
Jane E. Churpek
How can we assess quality of life in AML patients?
Progress in acute myeloid leukemia treatment – collaborating to develop targeted therapies